This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Outcomes assessed in the review
The outcomes derived from the literature were:
the probability and rate estimates for stroke and haemorrhage on aspirin and warfarin therapy for patients with AF and sinus rhythm; the efficacy and complications associated with LACA, amiodarone and rate control therapies; the mortality estimates; and the utilities weights associated with different health states, treatments and complications.
Study designs and other criteria for inclusion in the review
The authors stated that clinical data and utility values were derived from published sources, but did not clearly state whether a systematic review of the literature was undertaken. Limited information on the primary studies was provided. For example, expected survival was derived from US life tables. Meta-analyses and cohort studies were also used. No head-to-head studies were available for the efficacy of LACA in restoring sinus rhythm compared with medical therapy. Complication rates were obtained from large case series.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Fifty-one primary studies provided the clinical data.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
The baseline annual stroke risk in sinus rhythm was 0.9% (range: 0.4 to 1.3) in patients at moderate risk and 0.5% (range: 0.2 to 0.7) in patients at low risk.
The annual stroke risk in AF in patients treated with warfarin was 1.3% (range: 1.0 to 2.0) in patients at moderate risk and 0.7% (range: 0.4 to 1.0) in patients at low risk. extracranial haemorrhage, death, aspirin, warfarin (including monitoring), amiodarone, digitalis (including monitoring) and atenolol. The unit costs were presented separately from the quantities of resources used for only a few items. The costs were derived from multiple sources, including Medicare reimbursement rates (professional and facility costs), hospital accounting information, published literature, and the Red Book for wholesale drug costs. The sources of resource use were unclear. Discounting was relevant, as the long-term costs were evaluated, and an annual discount rate of 3% was used. The price year was 2004.
Statistical analysis of costs
The costs were treated deterministically in the base-case.
Indirect Costs
The indirect costs were not included in the economic analysis.
Currency

US dollars ($).
Sensitivity analysis
Univariate sensitivity analyses were carried out for all model parameters. Alternative values were mainly derived from published sources. A threshold analysis was also performed for 1-year LACA efficacy of 80% and annual stroke risk in patients with restored sinus rhythm, in order to assess the minimum level of LACA efficacy and stroke risk reduction needed to make LACA cost-effective. Finally, a second-order Monte Carlo simulation was used to carry out a multivariate sensitivity analysis. Specific probability distributions were assigned to model inputs (normal for nonskewed parameters, log-normal for skewed variables).
Estimated benefits used in the economic analysis
In the cohort of 65-year-old patients at moderate risk of stroke, the expected QALYs were 10.81 with rate control plus warfarin, 10.75 with amiodarone plus warfarin, and 11.06 with LACA plus warfarin. The corresponding expected LYs were 11.47 (rate control + warfarin), 11.45 (amiodarone + warfarin) and 11.55 (LACA + warfarin), respectively.
In the cohort of 55-year-old patients at moderate risk of stroke, the expected QALYs were 13.95 with rate control plus warfarin, 13.81 with amiodarone plus warfarin, and 14.26 with LACA plus warfarin. The corresponding expected LYs were 14.80 (rate control + warfarin), 14.75 (amiodarone + warfarin) and 14.88 (LACA + warfarin), respectively.
In the cohort of 65-year-old patients at low risk of stroke, the expected QALYs were 11.21 with rate control plus aspirin, 11.02 with amiodarone plus aspirin, and 11.40 with LACA plus aspirin. The corresponding expected LYs were 11.65 (rate control + aspirin), 11.60 (amiodarone + aspirin) and 11.70 (LACA + aspirin), respectively.
Cost results
The total lifetime costs in the 65-year-old cohort at moderate risk were $39,391 with rate control, $43,358 with amiodarone and $52,369 with LACA.
In the 55-year-old cohort at moderate risk, the total lifetime costs were $50,509 with rate control, $55,795 with amiodarone and $59,380 with LACA.
In the 65-year-old cohort at low risk, the total lifetime costs were $24,540 with rate control, $38,425 with amiodarone and $43,036 with LACA.
All patients at moderate risk received warfarin, while patients at low risk received aspirin in addition to LACA, amiodarone or medical rate control.
Synthesis of costs and benefits
Incremental cost-utility ratios were calculated to combine the costs and QALYs of the alternative strategies.
In all three cohorts, amiodarone therapy was dominated by rate control therapy. The incremental cost per QALY gained with LACA over rate control therapy was $51,800 in the 65-year-old cohort at moderate risk, $28,700 in the 55-yearold cohort at moderate risk, and $98,900 in the 65-year-old cohort at low risk.
The univariate sensitivity analysis showed that the most influential variables were the risk of stroke in AF with warfarin, the discount rate, LACA cost, the utility and haemorrhage risk with warfarin therapy, the rate of recurrence of AF after LACA, and the conversion rate to sinus rhythm with rate control therapy. LACA was substantially less costeffective when short-term time horizons (5 or 10 years) were used.
The threshold analysis suggested that, in the 65-year-old moderate-risk cohort, at the base-case estimate of 80% for 1-year LACA efficacy, an annual stroke risk in sinus rhythm of <= 0.76% and <=0.15% would result in a cost-utility ratio of less than $50,000 and $100,000 per QALY, respectively. Thus, the relative risk of stroke with long-term sinus rhythm should decrease by 42% and 11%, respectively, compared with patients in AF on warfarin (1.3% per year), to yield cost-utility ratios below these thresholds. Consistently, as LACA efficacy decreased, the stroke risk reduction with long-term sinus rhythm should increase for the same corresponding cost-utility ratio threshold. In the 55-year-old moderate stroke risk cohort, lower LACA efficacy rates were needed to satisfy the $50,000 and $100,000 per QALY thresholds, since younger patients live longer and are exposed to higher lifetime risk for stroke and haemorrhage from anticoagulant therapy.
The probabilistic sensitivity analysis showed that, in the 55-year-old moderate-risk cohort, LACA had a 4% probability of having a cost per QALY gained of greater than $100,000, and an 82% probability of having a cost per QALY gained of less than $50,000 in comparison with rate control therapy. More uncertainty was observed in the 65-year-old moderate-risk cohort, with 22% of simulations being greater than $100,000 per QALY gained and only 40% of simulations being less than $50,000 per QALY gained.
